Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Five year distribution agreement

4 Jan 2010 07:00

RNS Number : 9261E
Immunodiagnostic Systems Hldgs PLC
04 January 2010
 



Immunodiagnostic Systems Holdings plc

Five year distribution agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that Technogenetics s.r.l. ("Technogenetics") of Milan, Italy has signed a five year distribution agreement with A. Menarini Diagnostics ("Menarini") covering Europe for an automated test system, the Zenit RA, together with a panel of 21 tests for the diagnosis of autoimmune diseases. The Zenit RA is an OEM version of the IDS-iSYS system.

On 5 October 2009 IDS announced that it had signed an OEM manufacturing and supply agreement with Technogenetics, a subsidiary of Bouty S.p.A, the clinical diagnostics company (see RNS Reach number 1950A). As part of this agreement IDS will supply IDS-iSYS systems and consumables to Technogenetics on an OEM basis. These systems, branded as the Zenit RA, and consumables will be sold by Menarini as 'closed system' instruments throughout the whole of Europe and countries of the former Soviet Union such as Russia and Ukraine. Menarini is a leading company in the diagnostic field, with 14 direct subsidiaries, 1,000 employees and a consolidated turnover of 320 million Euros.

Commenting on the distribution agreement, Lorenzo Castellini, President of the Bouty Group, said: "We expect that over the five years the distribution agreement with A. Menarini Diagnostics will generate approximately €12 million in revenues from sales of diagnostic kits manufactured by Technogenetics with additional income from sales of instruments and ancillary reagents supplied by IDS."

Roger Duggan, CEO of IDS, said: "We're very pleased to see that our collaboration with Technogenetics is about to bear fruit and the deal signed between Technogenetics and Menarini significantly expands the route to market for Technogenetics’ autoimmune products. This can only enhance future sales of IDS-manufactured instruments and ancillary reagents across Europe, a great ‘upside’ to our agreement with Technogenetics.”

 

Enquiries:

 

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

David Evans, Chairman

 

Roger Duggan, CEO

 

 

 

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKKNDQBBKDODK
Date   Source Headline
17th May 20217:00 amRNSOffer for Immunodiagnostic Systems Holdings Plc
16th Apr 20217:00 amRNSFY21 Trading Update
29th Mar 20217:00 amRNSFDA EUA for automated IgG SARS-CoV-2 assay
27th Nov 20209:05 amRNSSecond Price Monitoring Extn
27th Nov 20209:00 amRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSLaunch of SARS-CoV-2 Antigen Rapid Tests
20th Nov 20206:22 pmRNSInterim Results - period ended 30 September 2020
26th Oct 20209:05 amRNSSecond Price Monitoring Extn
26th Oct 20209:00 amRNSPrice Monitoring Extension
23rd Oct 20204:35 pmRNSH1 Trading Update
9th Oct 20207:00 amRNSAssay to detect IgM SARS-CoV-2 antibodies launch
16th Sep 20207:00 amRNSNew TDM assays launched for use on the IDS-iSYS
14th Sep 20202:39 pmRNSDirector/PDMR Shareholding
27th Aug 20207:00 amRNSSARS-CoV-2 manufacturing agreement
13th Aug 20204:40 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:00 amRNSAutomated IgM assay to detect SARS-CoV-2
4th Aug 20204:18 pmRNSLaunch of automated IDS Cortisol assay
23rd Jul 20202:57 pmRNSResults of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 202010:40 amRNSDirector/PDMR Shareholding
16th Jul 20201:45 pmRNSDirector/PDMR Shareholding
30th Jun 20209:05 amRNSSecond Price Monitoring Extn
30th Jun 20209:00 amRNSPrice Monitoring Extension
30th Jun 20207:00 amRNSLaunch of assay to detect SARS-CoV-2 antibodies
17th Jun 20208:35 amRNSPublication of Annual Report and Accounts
17th Jun 20207:00 amRNSFinal Results
12th Jun 20209:06 amRNSSecond Price Monitoring Extn
12th Jun 20209:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSAutomated assay to detect SARS-CoV-2 antibodies
17th Apr 20204:35 pmRNSFY20 Trading Update
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report
18th Oct 20194:35 pmRNSTrading Statement
25th Jul 20193:34 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement
11th Jul 20192:16 pmRNSDirector/PDMR Shareholding
5th Jul 201910:02 amRNSDirector/PDMR Shareholding
19th Jun 20197:05 amRNSPublication of Annual Report and Accounts
19th Jun 20197:00 amRNSFinal Results
22nd May 20192:05 pmRNSSecond Price Monitoring Extn
22nd May 20192:00 pmRNSPrice Monitoring Extension
18th Apr 20194:35 pmRNSFY2019 Trading Update
12th Mar 201911:55 amRNSChange of Auditor
7th Jan 20198:20 amRNSDirector/PDMR Shareholding
18th Dec 20181:42 pmRNSDirector/PDMR Shareholding
6th Dec 20185:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.